Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $223.00 Consensus PT from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $223.5714.

Several equities research analysts have issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Bank of America lifted their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Citigroup reiterated a “neutral” rating on shares of Krystal Biotech in a research note on Tuesday. Finally, Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brooklyn Investment Group grew its stake in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after buying an additional 105 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares in the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech in the first quarter valued at $29,000. AdvisorNet Financial Inc bought a new position in shares of Krystal Biotech in the third quarter valued at $30,000. Finally, Salomon & Ludwin LLC bought a new position in shares of Krystal Biotech in the third quarter valued at $33,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Up 0.2%

Shares of KRYS opened at $197.85 on Tuesday. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $207.84. The stock has a market capitalization of $5.73 billion, a P/E ratio of 40.21 and a beta of 0.65. The company has a 50 day moving average of $170.39 and a 200-day moving average of $152.92.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, sell-side analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).